WallStSmart
RXRX

Recursion Pharmaceuticals Inc

NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY

$3.30
-3.23% today

Updated 2026-04-29

Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
14.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Recursion Pharmaceuticals Inc (RXRX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$3.30
Consensus
$7.50
+127.27%
2030 Target
$8.00
+142.42%
DCF
—
—
4 analysts:
2 Buy2 Hold0 Sell

Management guidance

Recursion reported $754M in cash extending runway into early 2028 without additional financing, achieved fifth program milestone with Sanofi, and announced $300M at-the-market equity offering. Management highlighted clinical validation of AI Operating System in FAP and advancing diversified pipeline with wholly-owned and partnered programs.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$41.44
$0.5B Rev × 42x P/S
Base case (2030)
$8.00
$0.5B Rev × 32x P/S
Bear case (2030)
$21.71
$0.5B Rev × 22x P/S

Financial forecast — research-backed

Metric2023202420252027 (E)2028 (E)2029 (E)2030 (E)
Revenue$0.0B$0.1B$0.1B$0.2B$0.2B$0.4B$0.5B
Revenue growth—34.1%26.9%82.5%60.0%50.0%40.0%
EPS$-1.57$-1.66$-1.48$-0.87$-0.65$-0.35$0.25
P/S ratio——————32.0x
Implied price———$0.00$0.00$0.00$8.00

Catalysts & risks

Growth catalysts
+ AI-native drug discovery platform clinical validation in FAP and other therapeutic areas
+ Partnership milestone achievements with Sanofi and potential new pharma collaborations
+ REC-4881 clinical trial progression and data readouts across multiple indications
Key risks
- High cash burn rate with continued losses and dependence on external funding
- Early-stage clinical pipeline with execution risks and potential trial failures
- Insider selling activity and potential dilution from $300M equity offering program

Methodology

Recursion Pharmaceuticals Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 4 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 2, 2026.